As part of AP&T’s peer-review process, a technical check of this meta-analysis was performed by Dr. P. Collins.
1365-2036/asset/olbannerleft.gif?v=1&s=45db8c78d1d41c404034f2eaf7587620d5727843)
1365-2036/asset/olbannerright.gif?v=1&s=45518840b7e2e59fcc9d74113b13f4474a604878)
You have free access to this content
Meta-analysis: insulin resistance and sustained virological response in hepatitis C
Article first published online: 29 MAY 2011
DOI: 10.1111/j.1365-2036.2011.04716.x
© 2011 Blackwell Publishing Ltd
Additional Information
How to Cite
Eslam, M., Aparcero, R., Kawaguchi, T., Del Campo, J. A., Sata, M., Khattab, M. A. and Romero-Gomez, M. (2011), Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Alimentary Pharmacology & Therapeutics, 34: 297–305. doi: 10.1111/j.1365-2036.2011.04716.x
Publication History
- Issue published online: 4 JUL 2011
- Article first published online: 29 MAY 2011
- Publication data , Submitted 15 February 2011, First decision 28 March 2011, Resubmitted 7 May 2011, Accepted 8 May 2011, EV Pub Online 29 May 2011
References
- 1World Health Organisation. Weekly epidemiological record. Wkly Epidemiol 363 Rec 2002; 77: 41–8.
- 2
- 3. The history of the “natural history” of hepatitis C (1968–2009). Liver Int 2009; 29(Suppl. 1): 89–99.
- 4, , , . Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335–74.
- 5APASL Hepatitis C Working Party, et al. APASL Consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22: L615–33.
- 6, , , et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon α-2a and ribavirin. Hepatology 2008; 48: 1033–43.
- 7, , , et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitisC. N Engl J Med 2009; 15: 257–76.
- 8, , , et al. Insulin resistance impairs sustained virologic response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636–41.
- 9. Targeting host factors: a novel rationale for the management of hepatitis C virus. World J Gastroenterol 2009; 15: 3471–9.
- 10. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus, and cardiovascular disease: clinical implications. Am J Cardiol 2008; 102: 5L–9L.
- 11, , , et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840–8.
- 12, , , , , , . The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 2007; 45: 1164–71.
- 13, , , . Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 1135–9.
- 14, , . Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49: 831–44.
- 15, , , et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570–6.
- 16, , , et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48: 721–7.
- 17, , , et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009; 50: 712–8.
- 18, , , et al. Insulin resistance is a major determinant of sustained virologic response in genotype 1 chronic hepatitis C patients receiving preginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther 2009; 29: 46–54.
- 19, , , , , . Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010; 105: 1970–7.
- 20, , , , , , . Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48: 28–34.
- 21, , , et al. The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int 2011; 31: 66–74.
- 22, , , et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009; 58: 1662–9.
- 23, , , et al. nsulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006; 43: 64–71.
- 24, , , et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007; 45: 80–7.
- 25, , , et al. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol 2009; 81: 1032–9.
- 26, , , et al. Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C. Hepatol Res 2009; 39: 850–5.
- 27, , , et al. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. Antivir Ther 2009; 14: 631–9.
- 28, , , et al. Whole-body insulin sensitivity index is a highly specific predictive marker for virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients with genotype 1b and high viral load. Dig Dis Sci 2010; 55: 183–9.
- 29, , , et al. Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. J Viral Hepat 2010; 17: 475–80.
- 30, , , et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009; 51: 984–90.
- 31, , , , , . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9.
- 32, , , et al. Toward standardization of insulin immunoassays. Clin Chem 2009; 55: 1011–8.
- 33, , , Insulin Standardization Work Group, et al. Insulin assay standardization: leading to measures of insulin sensitivity and secretion for practical clinical care. Diabetes Care 2010; 33: 205–6.
- 34
- 35, , , et al. Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. Hepatology 2010; 52: 38–46.
- 36. Heterogeneous virologic response rates to interferon- based therapy in patients with chronic hepatitis C: who respond less well? Ann Intern Med 2004; 140: 370–81.
- 37, , , et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105–9.